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REVIEW

Space‑occupying brain lesions,
trauma‑related tau astrogliopathy, and ARTAG:
a report of two cases and a literature review
Adam D. Bachstetter1,2,3* , Filip G. Garrett3,4, Gregory A. Jicha3,5 and Peter T. Nelson3,4

Abstract
Astrocytes with intracellular accumulations of misfolded phosphorylated tau protein have been observed in
advanced-stage chronic traumatic encephalopathy (CTE) and in other neurodegenerative conditions. There is a
growing awareness that astrocytic tau inclusions are also relatively common in the brains of persons over 70 years of
age—affecting approximately one-third of autopsied individuals. The pathologic hallmarks of aging-related tau astrogliopathy (ARTAG) include phosphorylated tau protein within thorn-shaped astrocytes (TSA) in subpial, subependymal, perivascular, and white matter regions, whereas granular-fuzzy astrocytes are often seen in gray matter. CTE and
ARTAG share molecular and histopathologic characteristics, suggesting that trauma-related mechanism(s) may predispose to the development of tau astrogliopathy. There are presently few experimental systems to study the pathobiology of astrocytic-tau aggregation, but human studies have made recent progress. For example, leucotomy (also
referred to as lobotomy) is associated with a localized ARTAG-like neuropathology decades after the surgical brain
injury, suggesting that chronic brain injury of any type may predispose to later life ARTAG. To examine this idea in a
different context, we report clinical and pathologic features of two middle-aged men who came to autopsy with large
(> 6 cm in greatest dimension) arachnoid cysts that had physically displaced and injured the subjects’ left temporal
lobes through chronic mechanical stress. Despite the similarity of the size and location of the arachnoid cysts, these
individuals had dissimilar neurologic outcomes and neuropathologic findings. We review the evidence for ARTAG in
response to brain injury, and discuss how the location and molecular properties of astroglial tau inclusions might alter
the physiology of resident astrocytes. These cases and literature review point toward possible mechanism(s) of tau
aggregation in astrocytes in response to chronic brain trauma.
Keywords: Tangles, NFTs, PSP, TBI, Tauopathy, Meninges, FTLD
Introduction
Much remains unknown about astrocytes in healthy
and diseased states. Here we discuss a specific subset of
astrocyte pathology, related to a hypothesis that localized
trauma can induce tau astrogliopathy, which is similar in
appearance to age-related tau astrogliopathy (ARTAG).
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It has recently become clear that chronic traumatic
encephalopathy (CTE) is associated with both neuronal
and glial tau pathology [1, 2]. Further, even decades after
neurosurgical procedures severing frontal white matter tracts (leucotomies), the frontal cortical tissue that
was traumatically affected tended to contain astrocytes
with abnormal tau accumulations [3]. These observations
raised intriguing questions about human astrogliopathy
seen commonly at autopsy, and the inter-relationships
between brain trauma and astrocytic tau proteinopathy. This review includes a presentation of two cases
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that experienced chronic mechanical stress induced by
large, localized, space-occupying brain lesions (arachnoid cysts), examined for ARTAG and other pathologies.
These case reports are followed by a broader discussion of relevant scientific literature, focusing on human
studies.

Case reports
Arachnoid cysts are non-neoplastic alterations of the
leptomeninges resulting in a fluid-filled space between
the brain or spinal cord and the arachnoid membrane.
Arachnoid cysts usually arise from arachnoid membrane splitting in early development, although secondary cysts have been reported following head trauma [4,
5]. In adults, arachnoid cysts are often clinically silent
and may persist for decades [6, 7]. We present clinical
and pathologic findings from two adult males with large
arachnoid cysts. Note that in keeping with terminology
applied in other conditions [8, 9], we distinguish between
ARTAG (concept and disease) and the relevant neuropathologic hallmarks (ARTAG–NC); likewise for CTE
and CTE–NC.
Case 1 A Caucasian male who was part of the University of Kentucky Alzheimer’s Disease Center longitudinal
research cohort [10] came to autopsy at age 72 following
a complex neurological history. His mother died with
unspecified dementia, and his maternal grandmother had
ALS. He worked in the field of clothing manufacture and
retired at age 55. Progressive dementia was first noted
at age 66, characterized by aggressive behavior that was
clinically compatible with a frontotemporal syndrome.
The subject’s history was also notable for epilepsy (complex-partial seizures), type II diabetes, depression, intermittent alcohol use (up to a 1L whiskey/week), and there
was a clinical note of “post-Polio syndrome”. Reports of
possible football-related concussions in high school were
noted, as well as falls in late life, but more detailed information on closed head injury and brain trauma were
lacking in the medical and research records. Final MiniMental State Examination score at age 70 was 17, final
global clinical dementia ratings (CDR) scale score was 2,
and final CDR “sum of boxes” = 13, indicating dementia
of moderate severity. The patient died of acute cardiopulmonary arrest, unrelated to his dementia syndrome.
Four years before death, a head computed tomography
(CT) scan was performed as part of his seizure workup
which revealed a large arachnoid cyst within the left temporal fossa and Sylvian region (Fig. 1a). Neurosurgical
intervention was not pursued, in favor of observation. In
serial CT scans performed over the subsequent years, the
cyst remained stable in size, with progressive global brain
atrophy notably increasing over time.
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On post-mortem examination, the left side of his brain
showed a large evacuated area measuring 75 × 50 × 30
mm (Fig. 1b). The lesion was adjacent to the left Sylvian
fissure and resulted in extensive encroachment on the
anterior temporal lobe, completely exposing the left middle cerebral artery from the ventral aspect (Fig. 1a, b).
There was marked deformation and atrophy of the medial
temporal lobe structures, and evidence for grossly apparent orbitofrontal subpial hemorrhage or contusion.
Microscopic examination confirmed that the cyst lining
comprised a delicate fibrous membrane with areas of an
intact single layer of cells (arachnoid cells) and scattered
foci of meningothelial cells. In the orbitofrontal cortex
where discoloration (subpial hemorrhage) was noted on
gross exam, the same area showed chronic degenerative
changes including localized necrosis, neuropil rarefaction, and abundant hemosiderin-laden macrophages (not
shown). A neurodegenerative assessment revealed an
intermediate level of Alzheimer’s disease neuropathologic changes (ADNC): (Thal phase 5; Braak NFT stage
IV; Frequent neuritic plaques). The 2012 NIA-AA consensus ABC score was A = 3, B = 2, C = 3. In addition,
immunohistochemical stain for aberrantly hyperphosphorylated tau proteins (PHF-1 antibody [11]) displayed
features of both CTE–NC (Fig. 2) and ARTAG–NC
(Fig. 3). The CTE–NC-like changes included patchy
distribution of neuronal PHF-1+ tau at sulcal depths
of the cerebral cortex (Fig. 2). Several cerebrovascular
pathologies were also identified, including small chronic
ischemic infarcts.
While CTE–NC-like intraneuronal tauopathy was
observed focally, the ARTAG–NC-like pathology was
more extensive (Fig. 3). Numerous TSAs were seen
within the white matter of the neocortex (frontal, temporal and parietal lobe) and the medial temporal lobe structures (amygdala, entorhinal cortex, and hippocampus).
Many TSAs were present subjacent to the pia mater. The
cortical regions adjacent to the arachnoid cysts showed
prominent astrocytic tau accumulation arranged along
small vessels at the depth of the sulci (Fig. 3d). The distribution and proximity of the CTE–NC and ARTAG–NC
to the arachnoid cysts raised the question of whether this
large space-occupying lesion induced the tau proteinopathy through chronic mechanical stress.
Case 2 A Caucasian male was evaluated post-mortem
by the University of Kentucky Pathology Department at
age 64. He had previously been employed at a commercial nursery and used spray insecticides regularly on the
job but retired before age 40. There was no known family
history of dementia. Medical records indicated the presence of a “congenital” arachnoid cyst. His medical history
was otherwise complex. He underwent a double lung
transplant at age 57 years due to idiopathic pulmonary
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Fig. 1 Clinical (premortem) computerized tomography (CT) scans, and photographs of brain after autopsy and fixation, in two cases with large
arachnoid cysts. Case #1 is a male, 72 years old at death. This CT scan (a) was acquired at age 68. (b) The brain at autopsy following fixation from
Case #1 shows the large left-sided arachnoid cyst cavity. Both the anterior temporal lobe and the orbitofrontal frontal lobe are affected by the
lesion. Note that on the surface of the frontal cortex within the cyst cavity there is discoloration (white arrow). By contrast, the right side lacks
evidence of indentation or contusion in the orbitofrontal cortex. Case #2 is a male, 64 years old at death. The CT scan (c) was acquired at age 56.
As seen in the brain at autopsy following fixation (d), the arachnoid cyst is larger in the rostral-caudal axis in Case #2 in comparison to that of Case
#1. However, the lesion is shallower—the affected region is smaller in the dorsal–ventral axis, and there was less impact on the orbitofrontal cortex
(black arrow) in Case #2 compared to Case #1

fibrosis, and was on tacrolimus. He had advanced liver
disease with biopsy-diagnosed sarcoidosis, chronic CMV
viremia (taking valacyclovir 900 mg twice daily) and
rheumatoid arthritis treated with chronic steroids. At age
54, he “sustained a right-sided intracranial hemorrhage”
and reportedly underwent craniotomy and surgical
evacuation that left him with a partial facial hemiplegia.
The arachnoid cyst was visualized at the University of

Kentucky radiographically (shown in Fig. 1c) at age 56.
Neurosurgical intervention was not pursued, in favor of
observation. Serial CT scans performed at ages 58 and 62
years showed that the cyst remained stable in size. At age
60, he was seen by Neurology for parkinsonism, which
was attributed to a medication (metoclopramide) sideeffect. Concerns were raised about short-term memory
loss at that evaluation, but cognitive impairment was
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Fig. 2 CTE-like neuronal pathology in frontal cortex (middle frontal gyrus) of Case #1. (a) Low magnification of H&E-stained section shows the
location (white box) of the CTE-like perivascular cluster of phosph-tau (p-tau) illustrated in adjacent PHF1 + stained section (b). A single cluster of
PHF-1 + staining seen in the depth of the cortical sulci (B, black arrow). (c) At a higher magnification the large vessel (black arrow) is surrounded by
p-tau + neuronal and astrocyte staining

never formally diagnosed. No other salient neurological
symptoms were noted in the medical record review.
On post-mortem examination, the brain showed
an evacuated area on the left side measuring
80 × 35 × 30 mm (Fig. 1c, d). Compared to the arachnoid
cyst seen in Case #1, this lesion did not appear as impactful on the orbitofrontal cortex, but still caused significant
distortion of the temporal lobe. Microscopic examination
confirmed the arachnoid nature of the cyst and revealed
severe, widespread small vessel disease, including arteriolosclerosis, widening of the Virchow–Robin spaces,
and perivascular pigment-laden macrophages. Sections
sampled from near the arachnoid cyst were negative for
AD–NC (neurofibrillary tangles and neuritic plaques);
however, scant p-tau immunoreactive structures were
focally present within the medial temporal lobe (Fig. 4).
The p-tau immunoreactivity was seen adjacent to the
ependymal lining of the lateral ventricle (inferior horn)
(Fig. 4a) and occasionally surrounding Virchow–Robin
spaces of the parenchymal arterioles (Fig. 4b).

Literature review: astrocytes, brain injury, and tau
protein
Clinical and biologic features of Cases #1 and #2 relate
to three research domains: astrocytes; the sequelae of
chronic mechanical stress and brain trauma; and tau
pathobiology. Astrocytes are the most numerous cell
type in the CNS, serving fundamental roles in support
of brain function and regulating brain energy metabolism [12, 13]. Astrocytes also sustain synaptic activity and
homeostasis [14], and contribute to CNS inflammatory
signaling [15, 16]. The astrocyte glia limitans is a critical
anatomic domain at the blood–brain-barrier and at the

interface with the meninges [17]. Astrocytes also help
remove cellular waste via glymphatic flow [18]. Given the
many necessary functions of astrocytes in CNS physiology, astrocytic failure may contribute to synaptic dysfunction, neuronal loss, and neurodegeneration through
a number of biologic mechanisms [19–21].
Astrogliopathy is a term used to describe a spectrum
of astrocyte changes associated with injury or disease.
Astrogliopathy can be divided into reactive astrogliosis or
astrocytopathy [22], with the caveat that neither of these
processes are thoroughly understood. The term reactive
astrogliosis refers to astrocytic responses to changes in the
environment. Following brain injury, reactive astrogliosis
walls off the area of injury creating a functional border
(“glial scar”) limiting molecular infiltration and recruitment of immune cells into the parenchyma [17]. With
the proliferation of astrocytes and a loss of the astrocyte
domain structure, a glial scar is an extreme example of a
reactive astrocyte change, whereas many different alterations in brain physiology or disease may cause a milder
reactive astrogliosis [22]. Reactive astrogliosis is typically
both neuroprotective and reversible [22].
Astrocytopathy, in contrast, is a term which describes
degenerative remodeling of astrocytes, and is linked to
many different brain diseases. For example, Alexander’s
disease is a primary astrocytopathy caused by the overexpression of the intermediate filament glial fibrillary
acidic protein (GFAP) [22]. Although primarily linked to
an astrocytic protein overexpression, Alexander’s disease
is associated with misfolding of at least one other protein—TDP-43 [23]. ARTAG and severe (advanced-stage)
CTE are astrocytopathies characterized by astrocytic tau
inclusions.
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Fig. 3 Phospho-tau (p-tau) immunohistochemistry in the left fronto-parietal region of Case 1. In the low-magnification photomicrograph (a), the
pia mater is near the bottom and white matter (WM) near the top. This is a section of the left fronto-parietal cortex, which is caudal to the region
most directly impacted by the arachnoid cyst, and shows widespread p-tau (PHF-1) immunoreactivity in the subpial, gray matter, and white matter
regions. In each of these compartments there is prominent staining of p-tau surrounding small blood vessels, and also in cells with morphologic
features of astrocytes. Subpial staining is demonstrated in a small sulcus (b) and additional subpial staining is shown at low power in the adjacent
gyrus (blue arrow in a). (c) White matter shows p-tau cells with astrocyte morphology, as well as staining around blood vessels resembling
astrocyte foot processes (blue arrow). (d) The astrocytic p-tau in gray matter highlight pericapillary staining (blue arrows); the inset shows compact
p-tau + cells with astrocyte features (e)

The normal functions of tau protein are debated [24–
26] and the roles for tau proteins in glial cells are mostly
unknown. In the adult human brain, six tau isoforms
are generated by alternative splicing of the microtubule
associated protein tau (MAPT) gene. Depending on
whether the proteins contain three or four carboxy-terminal tubulin-binding domains (“repeats”), the proteins
can be classified as 3R or 4R tau, respectively [27, 28].
Immunohistochemical studies showed that astrocytes in

ARTAG–NC and CTE–NC are negative for 3R tau and
positive for 4R tau [29, 30].
To date, ARTAG–NC has not been reported in animal models in response to injury [31]. Yet it must be
emphasized that rodents do not develop tauopathy in
aging as humans do [32], and studies of genetically modified rodent models have primarily focused on neuronal
tau [31]. The lack of astroglial tauopathy was mostly
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Fig. 4 Sparse glial phospho-tau (p-tau) immunohistochemistry in Case 2. In this case, p-tau (PHF-1) immunoreactive structures were much
more sparse, mostly non-neuronal, and were apparent in the medial temporal lobe. (a) In the hippocampus, p-tau immunostaining was found
surrounding the rostral fringe of the inferior horn of the lateral ventricle (blue arrows; the ependymal lining denoted with an asterisk). Note that
a few TSAs are stained (e.g., magenta arrow). (b) Shows p-tau immunoreactivity surrounding Virchow–Robin spaces of arterioles (blue arrow).
Scattered p-tau + cells with delicate glial processes were also observed, such as that shown in (c) from the left-sided temporal cortex

described in engineered mice with human tau transgenes
driven by neuron-specific promotors that develop solely
neuronal rather than glial tau inclusions. The animal
models’ inability to recapitulate human tau changes in
response to brain injury could also be due to species difference in the native tau protein sequence, and/or kinases
that contribute to the development of a tau astrogliopathy, as well as species differences in brain size and structure [33–36]. Thus, despite the similarities between the
astroglial tau inclusions seen in CTE and ARTAG, there
are few experimental model systems to study the pathology. The human phenomenology of tau astrogliopathies
(as in other diseases) will likely prove informative. A goal
of the present review is to discuss the relevant observations in human brains, that may aid in the development
of mechanistic hypotheses for the development of tau
astrogliopathy.

Inter‑relationships between CTE and ARTAG:
evolving concepts
Associated with repetitive head injuries, CTE was first
studied in boxers as dementia pugilistica or “punchdrunk syndrome”, with subsequent research on American
football players and other elite athletes engaged in contact sports where closed head injury is common [37, 38].
According to the current criteria, the CTE–NC pathognomonic lesion is p-tau+ neurofibrillary tangles surrounding small blood vessels, in a patchy distributions
at sulcal depths of the cerebral cortex [2, 39]. CTE–NC
requires the presence of p-tau immunoreactive neurons

with or without p-tau immunoreactive astrocytes; however, these lesions commonly coexist [2, 39, 40]. The
distribution of tau pathology in CTE–NC and ARTAG–
NC suggests some shared etiology [41–43]. Further, the
presence of tau pathology in astrocytes in cases with
CTE–NC suggests that ARTAG–NC could be a response
of astrocytes to chronic mechanical stress or repetitive
acute traumatic brain injury [1, 2, 43].
Whether a single moderate-to-severe TBI leads to
CTE–NC is debated [1, 44–47]. Arena et al. [1] evaluated a series of cases with CTE–NC for astroglial tau
and compared those cases to other tauopathies including ARTAG, AD, corticobasal degeneration (CBD), primary age-related tauopathy (PART), Pick’s disease (PiD),
and progressive supranuclear palsy (PSP). Astrocyte tau
in CTE–NC shared molecular properties with ARTAG
cases. That is, the p-tau+ astrocytes expressed only 4R
tau, similar to ARTAG-p-tau+ astrocytes, while neurons
in CTE express both 3R and 4R tau, similar to AD [43].
Cherry et al. [48] examined 99 cases of CTE–NC for the
presence of 3R and 4R tau. Neurons expressed both 3R
and 4R tau pathology, while astrocytes only expressed
4R tau pathology. However, astrocyte tau changes were
only found in the more advanced (Stage III/IV) CTE–NC
cases. Intriguingly, p-tau+ astrocytes increased with age.
A tipping point was seen in the sixth decade of life, with
the percentage of p-tau+ astrocytes increasing linearly
into the seventh and eight decade of life, at which point
astrocytes accounted for at least 50% of the 4R tau+ cells
in the perivascular lesions [48]. Many questions remain
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Fig. 5 Illustration of morphology and location of aging-related tau astrogliopathy neuropathological changes (ARTAG–NC). (a) Phosphorylated
tau protein (p-tau) immunopositive astrocytes can broadly be found in five parts of the brain. (The illustration is not meant to be specific for any
neuroanatomical region of the brain). TSAs are seen in the border-associated astrocytes of the subpial (b) and subependymal borders (c) (location of
C not shown on A). (d) Perivascular astrocytes are the third border associated TSA. (It is not yet defined if these are exclusively arterial or are also venous
associated astrocytes). (e) TSAs are also seen in the white matter. (f) In the gray matter, GFAs are the second disease-defining astrocyte morphology

about the importance of intrinsic (including genetic)
factors, injury physics, and the how idiosyncratic single-trauma (TBI) and multiple/repetitive trauma (CTE)
conditions relate to these findings.
As awareness grows of CTE and its public health
impact, case reports and cohort studies have accumulated outside the realm of contact sports [49–53]. These
have included subjects with trauma from reported falls,
vehicular accidents, military service, and other injuries
that are independent of sports-related injuries. Interestingly, much of the reported pathology in such cases
appears to be ARTAG–NC—perivascular p-tau+ astrocytes. However, there are also examples of p-tau+ neurofibrillary tangles at sulcal depths of the cerebral cortex
in non-sports related CTE [2, 53].
In the two current cases with large arachnoid cysts,
the individual (Case #1) with ARTAG–NC and CTE–NC
like pathology had prior history of playing contact sports
with documented concussions. In contrast, the person
without ARTAG–NC or CTE–NC pathology (Case #2)
had no known history of contact sports or TBI. These
results support the connection between TBI and ARTAG
but also suggest that TBI is not the sole driver of the
ARTAG–NC seen in these cases. We cannot rule out that

the nature of the arachnoid cyst in Case #1 was deeper
and therefore itself caused added chronic mechanical stress related injury to the brain, as indicated by the
bruising along the cyst cavity (Fig. 1). This hypothesis is
supported by the findings of minimal/incipient ARTAG–
NC in Case #2, that also demonstrated chronic mechanical stress related injury to the brain, without a history of
acute TBI or closed head injury (Fig. 1).
The community-based autopsy study by Forrest et al.
[54] provided insights into the prevalence of CTE and
ARTAG in a high-quality European cohort. This study
included 310 individuals aged 76-91 years old and evaluated multiple brain regions for the presence of CTE–NC
and ARTAG–NC. One-third of the cases in this cohort
were found to have ARTAG–NC. The findings of a
very substantial proportion of elderly brains harboring ARTAG–NC are consistent with results from other
community-based and clinic-based autopsy cohorts [30,
55–57]. It was also described that neocortical, as opposed
to limbic or brainstem ARTAG–NC, was most strongly
associated with dementia status [57].
Forrest et al. went on to explore the connection
between a reported history of TBI and ARTAG–NC
[54]. Of the 310 people included in the study, 67 people
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Fig. 6 Comparison of white matter fibrous versus tau + thorn-shaped astrocytes. A summary of the molecular characteristics of healthy white
matter fibrous astrocytes is shown in comparison to reported changes in white matter thorn-shaped astrocytes. The text highlighted in red are
known changes in the thorn-shaped astrocytes in ARTAG

completed a self-reported TBI questionnaire. Only six
subjects reported a loss of consciousness for at least 10
minutes (this number may reflect an underreporting
or recall bias). If a single brain trauma caused ARTAG,
ARTAG–NC would be expected in those six cases. However, only two of six cases with documented TBI were
found to have ARTAG–NC—the same 1/3rd proportion
as in the cohort overall. These results support the null
hypothesis and underscore that more data is required
about the relationship between clinical TBI history and
ARTAG neuropathology.
In a novel approach to the study of brain trauma, Shively
et al. [3] examined the brains of five individuals who underwent surgical leucotomy at least 40 years prior to death. The
leucotomized subjects were schizophrenics and the study
included matched subjects with schizophrenia that did not
have leucotomy [3]. Thus, they controlled for severity, time,
and location of the brain injury, while avoiding some of the
recall bias inherent to sports and TBI studies.
In the leucotomy cases, as expected, pathological
evaluation showed severe, localized white matter damage. CTE–NC was also present in some cases, including
p-tau in neurons in cortical sulcal depths and around
small blood vessels [3]. However, the dominant pathology

was ARTAG–NC-like changes (astrocyte p-tau) and
not neuronal CTE–NC pathology. The matched control cases lacked ARTAG–NC or CTE–NC changes [3].
Around the surgical lesion in the white matter, a dense
astroglial scar was present along with subpial astrocytosis at the proximal depth of the overlying cortical tissue’s
sulci. Despite the severity of the subcortical white matter
injury in the leucotomy cases, the gray matter was relatively intact; and cortical astrogliosis was absent. We note
that Okamura et al. [58] also reported neuronal and glia
p-tau pathology in 2 Japanese cases following leucotomy
and provided a summary of previous neuropathological
evaluations of leucotomy cases [58].
Shively et al. [3] tested whether tauopathy in astrocytes was a predictable component of glial scars or is a
more idiosyncratic degeneration of a subset of astrocytes.
Using serial sections, they stained for GFAP+ astrogliosis and p-tau. Despite the dense GFAP+ staining in
the white matter adjacent to the cystic space-occupying
lesion border, there was no p-tau staining in adjacent
serial sections [3]. The lack of neuronal or astrocyte p-tau
is informative as it shows that ARTAG–NC is not simply an unselective response to injury. Moreover, p-tau+
astrocytes were seen at the pia surface in depths of the

Bachstetter et al. acta neuropathol commun

(2021) 9:49

sulci. In contrast to the intense astrogliosis seen at the
border of the cystic space-occupying lesion, where
ARTAG–NC was not seen, the subpial ARTAG–NC positive regions demonstrated only limited GFAP+ astrogliosis [3]. This suggests that astrogliosis alone was not
the primary cause of ARTAG–NC. There must be other
contributing factors, which may be specific to particular
anatomic microdomains.
Shively et al. [3] suggested two hypotheses for the
neuropathologic changes seen in their study. The first
hypothesis was that axonal injury was the cause of the
lesions. In the second hypothesis, the sulcal depths were
more vulnerable to mechanical stress caused by the leucotomy procedure. Similar arguments for mechanical
stress at sulcal depths have been proposed for CTE. The
authors, however, stated their data supported the first
hypothesis that the p-tau accumulation resulted from
axonal damage. They further suggested that the accumulation of perivascular tau and the tau in the sulcal depths
might be associated with the clearance of tau from the
brain. They proposed that these locations were consistent
with tau clearance via a glymphatic flux [3]. That is, the
p-tau accumulation in the perivascular space and sulcal
depths amounted to a ring around the drain as tau left the
brain from injured axons. In our current case studies, it is
notable that the arachnoid cyst in Case #2 caused longterm deformity of the brain, with far milder ARTAG–
NC, underscoring that additional factors (intrinsic and
environmental) may play important roles.

Distinct populations of p‑tau + astrocytes
Astrocytic tau inclusions are not only seen in ARTAG.
Indeed, astrocytic tau changes can be a cardinal neuropathologic (if not pathognomonic) lesion in primary
tauopathies, including tufted astrocytes in PSP, astrocytic plaques in CBD, globular astroglial inclusions in
GGT, and ramified astrocytes in PiD [41, 42, 59]. Astrocytic tau changes in these primary tauopathies differ in
morphology and location from those seen in ARTAG–
NC. Importantly, as described in our case reports, there
are subregions of the brain that appear more vulnerable
towards the development of ARTAG–NC. Therefore,
to understand possible causes of ARTAG–NC and how
ARTAG–NC might alter brain physiology, it is important
to appreciate the heterogeneity of ARTAG–NC.
ARTAG–NC may include three populations of borderassociated astrocytes, as well as protoplasmic gray matter
and fibrous white matter astrocytes (Fig. 5). The astrocytes’ morphologic appearance defines the cells as TSA
and GFA. In CTE and in response to brain injury, much
of the ARTAG–NC is TSA. However, a different picture
may be seen in neurodegenerative disease. Notably, individuals defined as healthy controls lacked gray matter
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ARTAG–NC, while 32% of AD/PART cases and 37% of
Lewy body dementia cases had gray matter ARTAG–NC
[60]. These results do not rule out the involvement of
brain trauma as a contributor to ARTAG–NC. They do
suggest that there may be heterogeneity among ARTAG
subtypes, and it is important to consider differences in
location and type of ARTAG–NC found.
As shown in Fig. 5, TSAs may be found in three border
region-associated astrocytes, and some of the morphological features are shared across the different anatomical regions. This includes the TSA astrocytes at the
subpial (Figs. 3b, 5b) and subependymal border (Fig. 5c).
In these locations, the astrocyte processes of the TSAs
reach the outer surface of the brain (Fig. 5b) or the central ependyma lining the ventricles (Fig. 5c). The subpial
TSAs are likely marginal astrocytes, also known as interlaminar astrocytes. These are a relatively poorly studied
population of specialized glia that form layers of endfeet at the pial surface, thus forming the glia limitans in
the brain-meninges border. In humans, these marginal
astrocytes send long, thin projections into the deeper
cortical layers terminating in cortical layers II through
IV [61]. Subpial TSAs are most often found in the cerebral cortical lobes, amygdala, hippocampus, basal forebrain, lateral midbrain, pons, medulla oblongata, and
into the spinal cord [60]. Subependymal TSAs are seen
in the third ventricle, the inferior horn of the lateral ventricle, aqueduct of the midbrain and medulla oblongata,
and rarely in the anterior and posterior horn of the lateral ventricle [60].
The third border-associated ARTAG-vulnerable astrocytes are perivascular (Fig. 5d). The perivascular TSAs
can be seen near the subpial surface, or in gray (Fig. 3e)
or white matter (Fig. 3c) [60]. Subpial, subependymal,
and perivascular astrocytes maintain blood-brain and
brain-CSF-blood barriers, and regulate glymphatic flow
[18]. If perivascular ARTAG–NC was abundant in the
venous compartment, this could suggest a role in the
movement of CSF and drainage out of the brain, whereas,
if the perivascular ARTAG–NC was extensively in the
arterial compartment, this could impact cerebral blood
flow autoregulation. We identified ARTAG–NC surrounding Virchow–Robin spaces of arterioles (Fig. 4b)
and surrounding capillaries in the cortex (Fig. 3d). Prior
studies emphasized that ARTAG–NC can be found in the
arterial compartment [41, 60]. More work is needed to
evaluate ARTAG–NC associated with different cerebral
vascular segments quantitatively, and if trauma versus
neurodegenerative pathology causes a different vascular
localization pattern.
White matter is another compartment where TSAs are
found in ARTAG (Figs. 5e, 6). The white matter of the
medial temporal lobe has the highest likelihood of TSA,
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GFAs found in the gray matter are present most often
in the amygdala, basal ganglia, cortex, and brainstem [63]
(Fig. 5f ). As the name suggests, GFAs have a fine granular appearance by p-tau-immunostaining, that appears to
fill the cytoplasm of the protoplasmic astrocytes in the
gray matter. GFAs have been found to be the most prevalent type of ARTAG–NC [54]. Further clues suggest that
gray matter GFAs could be one of the earliest pathological changes associated with ARTAG–NC [54, 60, 62]. In
our cases, GFAs were not widely observed in the cortical
gray matter (Fig. 3d), suggesting that TSAs may be more
specific to trauma, while GFAs could be associated with
neurodegenerative pathology.

Fig. 7 MAPT (Tau mRNA transcript) expression in astrocytes from
human adult brain. Shown are results from three different single-cell
and single-nucleus RNAseq studies (from outside laboratories) which
analyzed mRNA transcripts in human brain samples. Pie charts (a, c,
e, g) show that the proportion of astrocytes that express MAPT was
remarkably similar (~ 1/4th of astrocytes evaluated express MAPT
transcript) in all three studies. Among the astrocytes that expressed
any MAPT (b, d, f), the amount of MAPT transcripts detected in
astrocytes was approximately the same as in neurons in the same
brains. In AD astrocytes that express MAPT (f), the level of MAPT
transcripts detected was higher than in MAPT expressing control
astrocytes

whereas the occipital lobe is the least likely [62]. Interestingly, the white matter of the corpus callosum, internal
capsule, or cerebellar peduncles tend to be unaffected by
ARTAG–NC [60]. The physiology of white matter fibrous
astrocytes are poorly understood in healthy and disease
states. By morphology, the fibrous astrocytes of the white
matter have fewer branches than the gray matter astrocytes. The fibrous astrocytes align radially in the direction of the axonal tracks. These astrocytes also lack the
tiling properties of gray matter astrocytes [61].

Tau expression and protein modifications relevant
to ARTAG
Little is known about tau expression (either transcription,
or translation from mRNA) within human astrocytes. Via
tubulin-binding domains, tau proteins may interact with
microtubules, which are certainly present in astrocytes.
Yet as far as we know, non-phosphorylated tau protein
has not been visualized in quiescent astrocytes.
At least three studies reported single-cell or singlenuclei RNAseq data on human brain tissue suitable for
studying MAPT transcripts in astrocytes. Their results
were highly similar with each other in some important ways (Fig. 7). The first study conducted single-cell
RNAseq on adult temporal cortex from individuals
undergoing surgery for refractory seizures [64] (Fig. 7a,
b). Using the authors’ cell type clusters, most astrocytes
(77%) had low or nearly undetectable levels of MAPT.
In comparison, 37% of neurons and 61% of oligodendrocytes had low or nearly undetectable levels of MAPT.
On average, astrocytes expressed 67% less MAPT than
neurons. Approximately a quarter of astrocytes express
MAPT transcripts, and, notably, this population(s) of
astrocytes express MAPT at similar levels to that of
neurons. The second study completed single-nucleus
RNAseq from the postmortem prefrontal cortex of 17
healthy control males as part of a study on major depressive disorder [65] (Fig. 7c, d). In these individuals, 75% of
astrocytes expressed no MAPT. Yet, the astrocytes that
did express MAPT again did so at comparable levels to
neurons. The third study performed single-nucleus RNA
sequencing from the postmortem entorhinal cortex of
six AD patients and six sex- and age-matched controls
[66] (Fig. 7e–g). Once again, approximately 3/4th of the
astrocytes did not express MAPT. Similarly, in the AD
brain, 74% of the astrocytes did not express MAPT. In
the astrocytes that did express MAPT transcripts, there
was a significant (p < 0.001) increase in MAPT expression
in the AD cases compared to control cases.
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Fig. 8 Two hypothesis of ARTAG development. (a) In the neuronal centric model, a neuron expresses the majority of the tau protein (1). The neuron
releases this tau protein (2) which (after trauma or axonal breakage) may be taken up by an astrocyte (3) during the glymphatic removal of the tau
protein. This leads to the accumulation of exogenous tau, and the seeding of aggregated astrocyte tau. (b) In the astrocyte centric model, most
healthy astrocytes express no or very low levels of MAPT. Changes in the brain environment—from an injury, aging, disease, or a combination
of factors—leads to a reactive astrocyte response (1), which may be centered around small blood vessels (2, 3). The reactive astrocytes then
upregulate the expression of MAPT and increase kinase activity (4), which leads to the hyperphosphorylation and aggregation of tau (5), causing
p-tau + aggregates in astrocyte cell bodies and perivascular foot processes (6)

The single-cell and single-nucleus RNAseq studies were
not informative about how the spatial localization of the
astrocytes corresponded with MAPT expression. We also
do not know if astrocytes upregulate MAPT when they
become reactive. Neurodegenerative disease can increase
astrocytic MAPT expression, suggesting that reactive
astrogliosis could lead to astrocytes making more tau.
However, the proportion of astrocytes that expressed
MAPT didn’t increase with AD, indicating heterogeneity
in astrocytes throughout healthy and diseased states. In
summary, much remains unknown about MAPT expression in astrocytes including the basis for spatial heterogeneity of the MAPT expression.
Phosphorylation of tau is a widely studied tau posttranslational modification, and the pattern of phosphospecific epitopes expressed by ARTAG cells has been
characterized [29, 43, 67]. Reactive astrocytes increase
expression of some kinases [68, 69]. For instance, the
mitogen-activated protein kinase (MAPK) are activated
by stress, damage associated molecular patterns, and
cytokines, and are known to be important pathways
driving neuroinflammation and glial activation [70].
The MAPKs, among others, can also phosphorylate tau.
TSAs were positive for the active (phosphorylated) form
for all three MAPK pathways (ERK, JNK, p38), as well as
GSK3B [29]. Ferrer et al. [67] completed phosphoproteomics on three control brain samples and three ARTAG
brain samples. Interestingly, GFAP and aquaporin 4 were
highly phosphorylated. They also found additional evidence for MAPK and cyclin-dependent kinases (CDKs)

involvement from the phosphoproteomics [67]. These
two studies imply that astrocyte activation may be driving high kinase activity in the astrocytes. This could be
stimulating neuroinflammation, as well as phosphorylating tau. However, it has not yet been shown if the p-tau+
astrocytes express more kinase activity than the p-tauastrocytes in brains with ARTAG–NC.
While they may be in some senses “reactive” to local
tissue injury or insult, p-tau+ astrocytes have less GFAP
staining and are smaller than p-tau-astrocytes from
healthy control brains; they also appear to be misshapen
[67]. Schwab et al. [71] explored a link between TBI and
markers of cellular senescence in astrocytes. Specifically,
they asked if a history of repetitive TBI increased γH2AX,
a marker of double strand DNA breaks, in astrocytes. The
increase in γH2AX was found in ependymal and subependymal cells and subpial astrocytes. This study did not
specifically evaluate ARTAG, however [71]. While evaluation of white matter TSAs found the cells negative for
ubiquitin, p62, beta-amyloid, and alpha-synuclein [29],
perhaps suggesting that the astrocytopathy see was due
specifically to tau misfolding. Of note, the p-tau+ astrocytes did express superoxide dismutase 2 (SOD2), and
it was suggested that the SOD2 may be a cellular senescence marker [29]. It is unclear whether SOD2 expression
contributed to or was a downstream effect of abnormal
tau inclusions in TSAs.
Another theme that emerges from human phenomenology is the presence of glial tau inclusions at border regions between micro-domains and at connection
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points between cells. The molecular underpinnings of
these observations are mostly unknown. Kovacs et al.
evaluated glial aquaporin-4 and Connexin-43 in ARTAG
cases [72]. Aquaporin-4 is a water-channel protein,
expressed at astrocyte “endfeet”, which plays an important role in glymphatic function in the CNS [18]. Connexin-43 is a major gap junction protein expressed by
astrocytes [73]. In areas with high astrocyte p-tau staining, connexin-43 and aquaporin-4 staining was increased
or remain highly expressed [72]. The study did not specifically test whether the cellular localizations of connexin-43, and aquaporin-4 was altered. Overexpression
and mis-localization of the proteins away from astrocytic
endfeet might alter the physiological function of these
proteins [18]. Further evaluation of these proteins and
other endfeet proteins in ARTAG–NC is warranted.

Pathologic mechanisms
Some of the potential disease-driving paradigms linked
to ARTAG–NC derive from prior studies focusing on
neuronal tau pathology. A growing body of evidence
demonstrates that tau paired helical filaments (PHF)
can promote further aggregation of tau in an amplifying,
feed-forward mechanism similar to, or at least analogous to, prion diseases. In the nucleation-elongation
mechanism, PHF tau “seeds” placed into the brain can
initiate and accelerate more tau aggregation in an autopropagating manner [27, 74]. This mechanism was supported experimentally using in vitro assays initially, but
numerous studies have now demonstrated that preformed aggregated tau or human diseased brain extracts
can accelerate tau aggregation in various animal models
[75–77]. Here we focus on the studies most relevant to
ARTAG–NC.
Tau seeds have been isolated from human brains with
multiple tauopathies, including glial tauopathies. When
injected into a mouse brain, tau seeds lead to trans-synaptic pathologic spreading that maintains the disease’s
tau strain identity. For instance, AD tau extracts will
seed neuronal tau, whereas PSP or CBD (human diseases
with abundant glial tauopathy) brain extracts will seed
glial tau [78]. In addition to the cell type specificity, the
tau isoform from the diseased donor, be it 3R or 4R tau,
were recapitulated in the recipient mouse: brain extracts
from AD cases seeded 3R and 4R tau, while PSP and CBD
brain extracts seeded 4R tau, and PiD seeded 3R tau [78,
79]. These studies showed that there are disease-specific,
cell type-specific, and, to some extent, isoform-specific
mechanisms underlying tau seeds.
Narasimhan et al. [80] asked if the formation of glia
tau required neuronal tau. Using mice with a neuronalspecific deletion of MAPT, they tested if CBD-tau or
PSP-tau could induce glial tauopathy. They found that
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CBD-tau injected mice had tufted astrocytes, and the
PSP-tau injected mice had coiled body inclusions in oligodendrocytes [80]. This underscores that glia can form
tau inclusions in the absence of neuronal-sourced tau.
This study did not generate an astrocyte-specific MAPT
knockout mouse to show that the aggregated tau was
from endogenous astrocyte tau as opposed to some other
cellular source.
Ferrer et al. [67] found evidence that ARTAG–NC
derived tau seeds were unlike seeds sourced from other
diseases, in that they did not maintain the disease phenotype. In this study, ARTAG–NC tau brain extracts
injected in the mice resulted in p-tau in neurons, astrocytes, and oligodendrocytes. The tau did not maintain
the 4R specificity, as the ARTAG–NC tau brain extracts
seeded both 3R and 4R tau [67]. As ADNC is a common
comorbidity with ARTAG–NC, there remains the possibility that the ARTAG–NC tau samples also contained
some ADNC tau, and that the latter was biologically
active in tau seeding experiments.
The mechanisms leading to ARTAG are poorly understood. However, our review of the literature suggests two
hypothetical models that are not mutually exclusive. In
the first model, neuronal injury causes the release of tau
protein seeds, which accumulate in astrocytes instead of
(or perhaps while) being cleared from the brain (Fig. 8a)
[3, 40]. This model assumes that the ARTAG–NC astrocytic p-tau is primarily of neuronal origin. As discussed
above, ARTAG–NC is commonly seen in CNS border
zones that are important for glymphatic removal of waste
[3]. Hence astrocytes may take up tau released from cells,
and the tau aggregates present in astrocytes may represent ingested remnants. A weakness of this hypothesis
is that it does not explain why ARTAG tau pathology is
exclusively composed of 4R tau.
A second hypothetical model proposes that brain
injury, in combination with age, lead to a transformation of astrocytes in ways that promote ARTAG–NC.
In this model (Fig. 8b), when astrocytes become reactive, they increase their expression of MAPT and have
high kinase activity. It is also possible that non-translated
MAPT mRNA could be translated in times of stress. The
increase in tau and high kinase activity cause hyperphosphorylation and aggregation of tau within tau+ astrocytes. This model assumes that astrocytes—or at least a
subset of astrocytes—make their own tau. As discussed
above, ~ 25% of the astrocytes in the human brain express
MAPT transcripts according to RNAseq experiments. In
brains with neurodegenerative disease, astrocytes that
express MAPT do so at higher levels than control brain
astrocytes [66]. Moreover, there are many brains with
ARTAG–NC that lack substantial neuronal tau pathology. Even in Case #2 in the present paper, we note that
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the minimal tau pathology observed was in glial appearing cells, within subependymal and perivascular microdomains. It is intriguing that this person, despite a very
long-term lesion in the brain, albeit causing only mild
mechanical stress, had minimal ARTAG–NC but also
had undergone long-term treatment with strong antiinflammatory drugs, given the possible role(s) played by
inflammatory mediators in tauopathy. However, the complex medical histories of both these individuals underscore the challenges of direct cause/effect inferences that
can be derived from human studies.
The limited number of astrocytes expressing MAPT
could help explain the selective vulnerability of specific
populations of astrocytes to ARTAG–NC and the patchy
nature of ARTAG–NC. With chronological age, astrocyte morphology and molecular signatures are altered
compared to young healthy brains, and astrocytes in
aged brain respond differently to a TBI than astrocytes in
young brains [20]. Further studies are required to explore
the astrocyte subpopulations that express MAPT and
their responses to brain injury.
We conclude that long-term space occupying lesions
that impose chronic mechanical stress on the brain (in
the examples described here, arachnoid cysts) may contribute to the development of ARTAG–NC in a stress
dose-dependent manner. That is, while both cases demonstrate ARTAG–NC changes, Case #2 with less destructive mechanical stress was associated with mild and
localized ARTAG–NC changes, whereas Case #1 with
a more severe mechanical stress injury was associated
with widespread and severe ARTAG–NC changes. In
this manner, the case reports presented and the literature review suggest that CNS trauma (chronic or acute
mechanical stress) can drive ARTAG–NC-like pathology.
The lesions’ morphologies and locations suggest that the
ARTAG–NC-like brain changes following injury from
mechanical stressors differs from that seen with neurodegenerative diseases. More work is required to test models
of ARTAG–NC development and the possible interaction
of seeding and tau aggregation models. Future work will
also be needed to understand the normal physiological
function of tau phosphorylation in astrocytes (if any),
and how ARTAG–NC changes astrocyte physiology.
As we learn more about ARTAG, we will gain a greater
understanding of how astrocytes contribute to the long
term sequelae of CNS trauma and age-related cognitive
decline.
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